In addition, increasing adoption of minimally invasive procedures over traditional surgical open heart procedures, reduction in
hospital stays, low risk of infection, minimal blood loss are further propelling the market. According to world health
organization (WHO), it has been estimated that the number of people suffering from cardiovascular diseases will increase to
22.2 million by 2030. The market for TMVR is expected to reach around USD 3.0 billion by 2022. However, there are certain
restraining factors which could hamper the growth of this market, which includes, high costs associated with the LMVD
implantation compared to other therapies available for CVD diseases.
Segment Covered
The report on global transcatheter mitral valve replacement market covers product segment. On the basis of product the
global transcatheter mitral valve replacement market is categorized into transapical implantation and transfemoral
implantation.
Make an Enquiry: https://www.infiniumglobalresearch.com/reports/enquiry/138
Geographic Coverage
The report provides regional analysis covering geographies such as Americas, Europe, Asia-Pacific, and Rest of the World. In
this section the key trends and market size for each geography is provided over the period of 2015-2023. The countries
covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India,
South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the
European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-
pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and
China. The APAC region is projected to experience a growth at a CAGR of x.x% over the period of 2017-2023.
Companies Profiled:
The report provides profiles of the companies in the global transcatheter mitral valve replacement market such as, Abbott
Laboratories, Edward Lifecsiences Incorporation, Micro Interventional Devices, Neovasc, Medtronic, Biotronik SE & Co. KG,
Colibri Heart Valve, Llc., Livanova Plc, Neochord Inc. and Coramaze Technologies Gmbh..
Infinium Global Research